Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

93 results about "Molecular function" patented technology

Molecular function. Molecular function describes activities, such as catalytic or binding activities, that occur at the molecular level. GO molecular function terms represent activities rather than the entities (molecules or complexes) that perform the actions, and do not specify where or when, or in what context, the action takes place.

Systems, devices and methods for translocation control

Some embodiments of the present disclosure are directed to systems, methods and devices for controlling the transit of a molecule across a nanopore. Some embodiments are directed to a device comprising a first compartment, a second compartment, a first pair of electrodes comprising a first electrode provided in the first compartment and a second electrode provided in the second compartment, a partition separating the first compartment from the second compartment, an orifice provided in the partition, a second pair of electrodes arranged proximate the orifice, the second pair of electrodes being functionalized with molecules, and a tunnel gap comprising the spacing between the second pair of electrodes.
Owner:ARIZONA STATE UNIVERSITY

RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression and / or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and / or activity of genes involved in Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro- RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous micro-RNA (miRNA) (e.g, miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules and are useful, for example, in providing compositions to prevent, inhibit, or reduce metabolic diseases.
Owner:SIRNA THERAPEUTICS INC

Prognosis marker for lung cancer and application thereof

InactiveCN109136370AImproved prognosisConvenience prognostic survival is very correlated by markerMicrobiological testing/measurementDNA/RNA fragmentationMolecular levelCvd risk
The invention discloses a prognosis marker for the lung cancer and application thereof. The long chain non-coding RNA gene RP11-434D9.1 of the marker is quite related to the prognosis period of patients with the lung cancer, through the marker and expression for detecting the marker, lung cancer prognosis is rapidly, accurately and conveniently predicted, the grading and layering of lung cancer risks are realized according to molecular levels, and patients with different grades of risks are separated obviously. Through co-expression analysis, 238 genes related to the long chain non-coding RP1-434D9.1 are found out, through an enrichment analysis on GO and KEGG pathways of the 238 genes, the molecular functions of the long-chain non-coding RP1-434D9.1 are found out, and important biologicalexperiment clues are provided for improving prognosis molecular diagnosis of the patients with the lung cancer and related medicine targets.
Owner:广州表观生物科技有限公司 +1

Application of taking oligopeptide and derivatives thereof as template molecule, and imprinting technology based preparation method of angiotensin synthetic receptor

The invention discloses an application of taking oligopeptide and derivatives thereof as a template molecule, and an imprinting technology based preparation method of an angiotensin synthetic receptor. The template molecule comprises any section of a peptide bond at a nitrogen end or a carbon end of an angiotensin II, and derivatives thereof, or any section of the peptide bond at the nitrogen end or the carbon end of an angiotensin I and the derivatives thereof. The application takes the template molecule as an imprint to prepare the angiotensin synthetic receptor; the angiotensin acceptor is prepared in a way that the template molecule, a function monomer, a cross-linking agent, a surface-active agent and the like are mixed according to a certain rate, and then an initiator is added. The acceptor is good in biocompatibility, can high selectively capture and neutralize the angiotensin II and the angiotensin I, and cuts off functions of the angiotensin II and the angiotensin acceptor (AT1) as well as functions of the angiotensin I and angiotensin converzyme (ACE), so as to control the blood pressure. The acceptor can be applied to separation, concentration and measuring of the angiotensin I or II.
Owner:SOUTH CHINA NORMAL UNIVERSITY

Molecular imprinting material as well as preparation method and application thereof

The invention relates to molecular imprinting material as well as preparation method and application thereof. The method comprises the following steps of: adding a template molecule, a functional monomer and a cross-linking agent into a container according to a proportion and then standing; adding a dispersing agent; finally adding an initiating agent and a hole-inducing agent into the container according to a proportion, controlling the temperature to react and obtaining a microparticle with the particle diameter ranging between 20 microns and 350 microns; refluxing and washing the obtained microparticle by a mixed solution of methanol/acetic acid in the container and detecting by GC (gas chromatography) till triazolam is not detected; washing by distilled water to neutrality; and drying in vacuum to constant weight to obtain the microparticle which is the needed triazolam molecular imprinting material. The prepared imprinting material can be directly used for enriching and separating the triazolam in urine, reduces the dosage of an organic solvent used when the triazolam is extracted by a liquid-liquid extracting method and is beneficial to the body health of an operator. The method does not need the protection of an inert gas, and the compounded material has the characteristics of small particle diameter and uniform distribution.
Owner:JIANGSU POLICE INST

Preparation method of halofuginone molecularly-imprinted solid-phase extraction small column and application

The invention provides a preparation method of a halofuginone molecularly-imprinted solid-phase extraction small column and an application and relates to the field of analytical chemistry. The preparation method comprises the following steps of: taking halofuginone as a template molecule, dissolving the template molecule into a porogen and adding a functional monomer at a low temperature for prepolymerization; then, mixing according to the molar ratio of the template molecule: the functional monomer: a cross-linking agent of 1:3-6:15-30, and preparing molecularly-imprinted polymer micro-spheres in a manner of initiated polymerization at a low temperate by adopting a suspension polymerization method and filling the rinsed, sieved, eluted and dried micro-spheres in an empty column tube of the solid-phase extraction column by adopting a wet process; and later, using the micro-spheres rinsed by acetone and methanol in sequence into selective adsorption, enrichment and purification of the halofuginone remained in animal derived foods. Compared with the existing solid-phase extraction column, the halofuginone molecularly-imprinted solid-phase extraction column prepared by the invention has the characteristics of strong specificity, convenience and simplicity in preparation, good recognition performance, low cost, easiness for realization of required instruments and reaction conditions and the like.
Owner:HENAN UNIV OF SCI & TECH

Multi-disease variable site analysis platform based on function network

The invention provides a multi-disease variable site analysis platform based on a function network. The multi-disease variable site analysis platform comprises a variable gene sequencing detection module, a function enrichment analysis module, a function network construction module, a function network mining module and a shared molecular network identification module, wherein the variable gene sequencing detection module is used for finishing the fundamental analysis of sequencing data; the function enrichment analysis module is used for utilizing a function enrichment analysis tool to analyze a variable gene function; the function network construction module is used for constructing the function network according to a function enrichment analysis result; the function network mining module is used for screening stable network modules from the function network; and the shared molecular network identification module is used for identifying molecular modules shared by different diseases according to the network module. The multi-disease variable site analysis platform analyses differences of different diseases on an aspect of genomic level, establishes an incidence relationship among the diseases from the perspective of molecular function, can systematically identity a shared modular function module among different diseases, effectively analyzes the nosogenesis of similar phenotype diseases, discloses differences between the diseases from the level of genome, increases the comprehensive understanding of the diseases and is favorable for clinic diagnosis and treatment.
Owner:WANKANGYUAN TIANJIN GENE TECH CO LTD

Long rigid spacers to enhance binding kinetics in immunoassays

The present invention relates to a device for detecting a target molecule within a sample comprising a sample container for the measurement of the target molecule within a sample, a first particle, wherein said first particle is functionalized with a first binding molecule capable of specifically binding to said target molecule, and a surface structure comprising a second binding molecule, wherein said surface structure covers a flat sensor or is present on a second particle, wherein said first particle is capable of binding said second binding molecule of the surface structure directly or indirectly; wherein said first and / or second binding molecule is indirectly attached to the particle surface of said first and / or second particle and / or the flat sensor surface via a long and rigid linker molecule; wherein the length and the consistency of said linker molecule is selected such as to result in an average extension length of said linker of more than 60 nm; and wherein the number of particle clusters or of bound particles is directly or inversely related to the amount of target molecules present in the sample. In a further aspect the present invention relates to a method of detecting the presence or amount of a target molecule within a sample. The present invention also describes the use of a particle according to the invention for detecting a target molecule within a sample.
Owner:SIEMENS MEDICAL SYST NETHERLANDS LTD

Preparation method and application of phloroglucinol molecularly imprinted polymers in plants

The invention relates to a preparation method and application of phloroglucinol molecularly imprinted polymers in plants. The method comprises the following steps of: mixing template molecules, a functional monomer and a cross-linking agent in a molar ratio of 1:(3-6):(15-30), and adding benzoyl peroxide and N,N-dimethylaniline which serve as redox initiators; dripping the mixture into a 3 to 8 percent polyvinyl alcohol 400 aqueous solution with stirring at the temperature of between 10 and 30 DEG C to obtain polymer microspheres; bleaching the polymer microspheres, sieving, eluting, drying and the like, and filling in a glass chromatographic column by a wet method; and moistening the polymer microspheres by using methanol and acetone sequentially to obtain a molecularly imprinted chromatographic column, so that the molecularly imprinted chromatographic column is used for the preferential adsorption and efficient enrichment of phloroglucinol substances such as hyperforin, adhyperforinand the like. Compared with the conventional chromatographic column, the prepared chromatographic column has the characteristics that the column is high in specificity, easy and convenient to prepareand low in cost, required instruments and reaction conditions are easy to implement, and the like.
Owner:HENAN UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products